The board of directors of Ocumension Therapeutics announced with the deepest sorrow that Mr. Lianming HE ("Mr. He"), an independent non-executive director, the chairman of the remuneration committee and a member of the audit committee and nomination committee of the Company, passed away on March 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.17 HKD | -1.65% | -0.14% | +7.34% |
04-15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
04-15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.34% | 647M | |
+32.95% | 700B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B | |
-1.81% | 157B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee